During a panel session at LSX World Congress in London, UK, on pharma business development and M&A in 2023 and beyond, four panellists from major pharma players broadly agreed that every deal needs flexibility on both sides to create the most value.
Chris Sheldon, SVP, global head of business development, said GlaxoSmithKline looked for three key things. The best deals, he said, were in the “intersection of great science, great financial...